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The nucleus shuns MAPK
 
pon differentiation, many cell types no longer proliferate in response to 
growth factor–activated MAPK. But MAPK has more than just mitogenic 
effects, and the cells must still activate and respond to MAPK to adjust lipid 
metabolism, protein synthesis, and other cellular functions. On page 689, 
Smith et al. identify a simple, yet until now elusive, mechanism by which cells 
uncouple MAPK’s proliferative effects from its other functions.
The strategy is based on compartmentalization. To bring about cell division, 
MAPK phosphorylates nuclear substrates such as Elk-1. But its nonproliferation 
substrates are cytoplasmic. So the simple fix to stop division in differentiated cells, 
as Smith and colleagues show, is to prevent MAPK from entering the nucleus. 
The group uses retinoic acid to induce differentiation in both embryonic stem 
cells and an embryonic carcinoma cell line. After treatment, activated 
MAPK—which had resided in both the nucleus and cytoplasm of undifferentiated 
cells—was restricted to the cytoplasm, as were its phosphorylated substrates.
Since nuclear export is not required for this 
change in localization, MAPK import must 
be blocked somehow. An intact cytoskeleton 
is required for the nuclear exclusion, so the 
authors speculate that differentiation changes 
actin and microtubule dynamics and cellular 
trafficking such that MAPK is continually 
transported away from nuclear pores. 
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Active MAPK (green) is ex-
cluded from the nucleus (red) 
after differentiation (right).
 
Muscle loves company
 
uture muscle cells recruit more cells to 
their cause, according to Gerhart et al. on 
page 739.
The group has isolated a pool of cells from 
the embryonic epiblast that seems to be com-
mitted even before gastrulation to form skeletal 
muscle. These cells express mRNA for the 
MyoD transcription factor and form skeletal 
MyoD
  epiblast cells form 
skeletal muscle (red) if the 
BMP pathway is blocked.
F
 
muscle in vitro if dissociated from other epiblast cells. Muscle formation 
in vitro requires a switch in expression from E- to N-cadherin, which also 
occurs as epiblast cells undergo gastrulation in vivo.
If separated from the muscle precursors, cells lacking MyoD retained 
E-cadherin and did not make muscle. However, when the MyoD
 
 
 
 cells were 
treated with medium from the muscle precursors, they expressed N-cadherin 
and formed skeletal muscle. BMP-4 was able to block this inductive effect, 
and inhibition of the BMP receptor in MyoD
 
 
 
 cells stimulated muscle 
formation. This suggests that the muscle precursors secrete a BMP antagonist, 
possibly Noggin, which recruits more cells to the muscle lineage.
The authors do not yet know whether this recruitment occurs via this 
mechanism in vivo but plan to test that question soon. They are hopeful 
that their results may be applied to stem cell–based treatments of degen-
erative muscle diseases. Injecting pluripotent cells with those that are 
already programmed to form muscle may produce more muscle than 
either cell type alone.
 
 
 
 
 
Antigens make a pit stop
 
n the road to antigen presentation, 
defective proteins are waylaid at rest 
stops in maturing dendritic cells (DCs), as 
shown by Lelouard et al. (page 667).
These rest areas, called DALIS, were 
previously identified by the group as clumps 
of ubiquitinated proteins that form transiently 
in newly activated DCs. Newly made proteins 
with translational or folding errors, called 
DRiPs, get ubiquitinated and are a major 
source of antigenic peptides. But the 
authors find that an arrest of DRiP processing 
at DALIS may put this process on hold.
Using an amino acid analogue that 
causes premature termination to induce 
and track DRiPs, the authors found that the 
DALIS are aggregates of DRiPs, which 
accumulate to high levels upon DC activation. 
DRiPs are probably targeted to DALIS 
directly by the translation apparatus, as 
continuing translation is needed to maintain 
the aggregates, and translation components 
are closely associated with DALIS.
The ubiquitination machinery, including 
the ribosome-associated E3 ubiquitin–ligase 
CHIP, is also found in DALIS. Ubiquitination 
normally triggers proteosome cleavage, 
thus allowing presentation of the resulting 
fragments. But DALIS somehow delay DRiP 
degradation for up to 16 h after DC activation. 
This implies that other DALIS components 
(as yet unidentified) tag the ubiquitinated 
DRiPs for temporary survival. The authors 
speculate that the delay offered by DALIS 
may favor the presentation of engulfed 
foreign peptides over the delayed endogenous 
antigens and thus might limit autoimmune 
responses.
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DRiPs (green) are sent to DALIS 
(red) in maturing DCs.
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